Document:

EX-10.1

 Exhibit 10.1 

SUPPORT AGREEMENT 

SUPPORT AGREEMENT (this “Agreement”), dated as of March 4, 2015, is by and among AbbVie Inc.
(“Parent”), Oxford Amherst Corporation, a Delaware corporation and a direct wholly owned subsidiary of Parent (“Purchaser”), and Robert W. Duggan (the “Stockholder”). 

WHEREAS, each Subject Stockholder is, as of the date hereof, the record and beneficial owner (as defined in Rule 13d-3 under the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), which meaning will apply for all purposes of this Agreement) of the number of shares of common stock, $0.0001 par value per share, of Pharmacyclics, Inc. (the “Company
Common Stock”), a Delaware corporation (the “Company”), set forth opposite the name of such Subject Stockholder on Schedule I hereto; 

WHEREAS, contemporaneously with the execution of this Agreement, Parent, Purchaser, Oxford Amherst LLC, a Delaware limited liability company
and a direct wholly owned subsidiary of Parent, and the Company are entering into an Agreement and Plan of Reorganization, dated as of the date hereof (as it may be amended from time to time, the “Merger Agreement”), which provides,
among other things, for Purchaser to commence a tender offer for all of the issued and outstanding shares of Company Common Stock (the “Offer”) and, following the completion of the Offer, the merger of Purchaser with and into the
Company (the “First Merger”) upon the terms and subject to the conditions set forth in the Merger Agreement (capitalized terms used herein without definition shall have the respective meanings specified in the Merger Agreement); and

 WHEREAS, as a condition to the willingness of Parent and Purchaser to enter into the Merger Agreement and as an inducement and in
consideration therefor, the Stockholder has agreed to enter into this Agreement. 
 NOW, THEREFORE, in consideration of the foregoing and
the mutual covenants and agreements set forth herein and in the Merger Agreement, and intending to be legally bound hereby, the parties hereto agree as follows: 

SECTION 1. Representations and Warranties of the Stockholder. 

The Stockholder hereby represents and warrants to Parent and Purchaser as follows: 

(a) Each of the persons listed on Schedule I to this Agreement (each such person including the Stockholder, a “Subject
Stockholder”) (i) is the record and beneficial owner of the shares of Company Common Stock (together with any shares of Company Common Stock which such Subject Stockholder may acquire at any time in the future during the term of this
Agreement, the “Shares”) set forth opposite such Subject Stockholder’s name on Schedule I to this Agreement and (ii) except as set forth in Schedule I to this Agreement, does not hold or have any beneficial ownership
interest in any other shares of Company Common Stock or any performance based stock units, 

 
restricted stock, deferred stock units, option (including any granted pursuant to a Company Equity Plan), or warrant to acquire shares of Company Common Stock or other right or security
convertible into or exercisable or exchangeable for shares of Company Common Stock. 
 (b) The Stockholder has the legal capacity to
execute and deliver this Agreement and to consummate the transactions contemplated hereby. 
 (c) This Agreement has been validly executed
and delivered by the Stockholder and, assuming this Agreement constitutes a valid and binding obligation of Parent and Purchaser, constitutes the valid and binding obligation of the Stockholder, enforceable against the Stockholder in accordance with
its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, and (ii) that the availability of the remedy
of specific performance or injunctive or other forms of equitable relief may be subject to equitable defenses and would be subject to the discretion of the court before which any proceeding therefor may be brought. 

(d) Neither the execution and delivery of this Agreement nor the consummation by the Stockholder of the transactions contemplated hereby will
result in a violation of, or a default under, or conflict with, any contract, trust, commitment, agreement, understanding, arrangement or restriction of any kind to which the Stockholder is a party or by which the Stockholder or the
Stockholder’s assets are bound. The consummation by the Stockholder of the transactions contemplated hereby will not (i) violate any provision of any judgment, order or decree applicable to any Subject Stockholder or (ii) require any
consent, approval, or notice under any statute, law, rule or regulation applicable to any Subject Stockholder other than (x) as required under the United States Securities Act of 1933, as amended (the “Securities Act”), the
Exchange Act, other similar securities laws and the rules and regulations promulgated thereunder and (y) where the failure to obtain such consents or approvals or to make such notifications, would not, individually or in the aggregate, prevent
or materially delay the performance by any Subject Stockholder of any of its obligations under this Agreement. 
 (e) Except as set forth
in Section 4, the Shares and the certificates, if any, representing the Shares owned by each Subject Stockholder are now, and at all times during the term hereof the Stockholder shall cause to be, held by such Subject Stockholder, by a nominee
or custodian for the benefit of such Subject Stockholder or by the depository under the Offer, free and clear of all liens, claims, security interests, proxies, voting trusts or agreements, options, rights (other than community property interests),
understandings or arrangements or any other encumbrances or restrictions whatsoever on title, transfer, or exercise of any rights of a stockholder in respect of such Shares (collectively, “Encumbrances”), except for (i) any
such Encumbrances arising hereunder (in connection therewith any restrictions on transfer or any other Encumbrances have been waived by appropriate consent), (ii) any rights, agreements, understandings or arrangements which represent a
financial interest in cash received upon sale of the Shares, and (iii) Encumbrances imposed by federal or state securities laws (collectively, “Permitted Encumbrances”). 

  
 2 

 SECTION 2. Representations and Warranties of Parent and Purchaser. Each of Parent and
Purchaser hereby, jointly and severally, represents and warrants to the Stockholder as follows: 
 (a) Each of Parent and Purchaser is a
corporation duly organized, validly existing and in good standing under the laws of the State of Delaware, and each of Parent and the Purchaser has all requisite corporate power and authority to execute and deliver this Agreement and to consummate
the transactions contemplated hereby, and has taken all necessary corporate action to authorize the execution, delivery and performance of this Agreement. 

(b) This Agreement has been duly authorized, executed and delivered by each of Parent and Purchaser, and constitutes the valid and binding
obligation of each of Parent and Purchaser, enforceable against each of them in accordance with its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting
enforcement of creditors’ rights generally and (ii) the availability of the remedy of specific performance or injunctive or other forms of equitable relief may be subject to equitable defenses and would be subject to the discretion of the
court before which any proceeding therefor may be brought. 
 (c) Neither the execution and delivery of this Agreement by each of Parent
and Purchaser nor the consummation by Parent and Purchaser of the transactions contemplated hereby will result in a violation of, or a default under, any contract, trust, commitment, agreement, understanding, arrangement or restriction of any kind
to which either Parent or Purchaser is a party or by which either Parent or Purchaser or their respective assets are bound. The consummation by Parent and Purchaser of the transactions contemplated by this Agreement will not (i) violate any
provision of any judgment, order or decree applicable to Parent or Purchaser or (ii) require any consent, approval or notice under any statute, law, rule or regulation applicable to either Parent or Purchaser, other than (x) filings under
the Securities Act, Exchange Act, other similar securities laws and the rules and regulations promulgated thereunder and (y) where the failure to obtain such consents or approvals or to make such notifications, would not, individually or in the
aggregate, prevent or materially delay the performance by either Parent or Purchaser of any of their obligations under this Agreement. 

SECTION 3. Tender of the Shares. 

(a) The Stockholder hereby agrees that the Stockholder shall (and shall cause each other Subject Stockholder to) validly tender (and deliver
any certificates evidencing) the Shares held by the applicable Subject Stockholder, or cause such Shares to be validly tendered, into the Offer promptly following, and in any event no later than the tenth (10th) business day following the
commencement of the Offer pursuant to Section 1.1 of the Merger Agreement in accordance with the procedures set forth in the Offer Documents, free and clear of all Encumbrances (other than Permitted Encumbrances); provided that Parent
and Purchaser agree that each Subject Stockholder may withdraw such Subject Stockholder’s Shares from the Offer at any time following 

  
 3 

 
the termination of this Agreement as otherwise provided pursuant to Section 7 hereof or upon the Offer being terminated in accordance with the terms of the Merger Agreement. For the
avoidance of doubt, (x) no Subject Stockholder shall be required, for purposes of this Agreement, to exercise any unexercised Company equity award held by such Subject Stockholder and (y) no Subject Stockholder shall have any obligation
under this Section 3(a) to tender (or caused to be tendered) any Shares into the Offer to the extent such shares constitute Company restricted stock awards or if that tender could cause such Subject Stockholder to incur liability under
Section 16(b) of the Exchange Act. 
 (b) If the Offer is terminated or withdrawn by Purchaser or the Merger Agreement is terminated
prior to the purchase of Shares in the Offer, Parent and Purchaser shall promptly return, and shall cause any depository or paying agent, acting on behalf of Parent and Purchaser, to promptly return all tendered Shares to the Subject Stockholders.

 SECTION 4. Transfer of the Shares; Other Actions. 

(a) Prior to the termination of this Agreement, except as otherwise provided herein (including pursuant to Section 3 or
Section 7) or in the Merger Agreement, the Stockholder shall not (and shall cause each other Subject Stockholder not to): (i) transfer, assign, sell, gift-over, hedge, pledge or otherwise dispose (whether by sale, liquidation,
dissolution, dividend or distribution) of, enter into any derivative arrangement with respect to, create or suffer to exist any Encumbrances (other than Permitted Encumbrances) on or consent to any of the foregoing (“Transfer”), any
or all of the Shares or any right or interest therein; (ii) enter into any contract, option or other agreement, arrangement or understanding with respect to any Transfer; (iii) grant any proxy, power-of-attorney or other authorization or
consent with respect to any of the Shares with respect to any matter that is, or that is reasonably likely to be exercised in a manner, inconsistent with the transactions contemplated by the Merger Agreement or the provisions thereof or
(iv) deposit any of the Shares into a voting trust, or enter into a voting agreement or arrangement with respect to any of the Shares. 

(b) Notwithstanding the foregoing, each Subject Stockholder may make (a) Transfers of Shares by will or other transfers for estate
planning purposes, to immediate family members, to a trust or other entity established for the benefit of such Subject Stockholder and/or for the benefit of one or more members of such Subject Stockholder’s immediate family, in which case any
such transferee shall agree in writing to be bound by this Agreement prior to the consummation of any such Transfer, (b) Transfers of up to 500,000 Shares in the aggregate with respect to all Subject Stockholders to charitable organizations, in
which case any such transferee shall agree in writing to be bound by this Agreement prior to the consummation of any such Transfer; and (c) Transfers of Shares as Parent may otherwise agree in writing in its sole discretion. 

(c) Upon receipt of payment in full for all of each Subject Stockholder’s Shares pursuant to the Merger Agreement, the Stockholder
agrees (and shall cause such Subject Stockholders to agree) that any and all rights incident to such Subject Stockholder’s ownership of Shares (including any rights to recover amounts, if 

  
 4 

 
any, that may be determined to be due to any stockholder or former stockholder of the Company), including but not limited to rights arising out of such Subject Stockholder’s ownership of
Shares prior to the transfer of such Shares to Purchaser or Parent pursuant to the Offer or pursuant to the Merger Agreement, shall be transferred to Purchaser and Parent upon the transfer to Purchaser or Parent of such Subject Stockholder’s
Shares. 
 SECTION 5. No Limitations in Capacity as Director or Officer. Nothing contained in this Agreement shall be deemed to
restrict the Stockholder from the exercise of his fiduciary duties in accordance with applicable Law in his capacity as a member of the board of directors of the Company or as an officer of the Company. 

SECTION 6. Further Assurances. Each party shall execute and deliver any additional documents and take such further actions as may be
reasonably necessary or desirable to carry out all of the provisions hereof, including all of the parties’ obligations under this Agreement. 

SECTION 7. Termination. 

(a) This Agreement, and all rights and obligations of the parties hereunder, shall terminate immediately upon the earliest to occur of the
following: 
 (i) termination of the Merger Agreement for any reason; 

(ii) the Effective Time; 

(iii) such date and time as (A) any amendment or change to the Merger Agreement or the Offer is effected without the Stockholder’s
consent that decreases the amount, or changes the form or (except with respect to extensions of the Offer in accordance with the terms of the Merger Agreement) timing, of consideration payable to all of the stockholders of the Company pursuant to
the terms of the Merger Agreement, or (B) any amendment, change or waiver to the Merger Agreement is effected without the Stockholder’s consent that materially and adversely affects the Stockholder; or 

(iv) the mutual written consent of Parent and the Stockholder. 

(b) Sections 8 and 11(e) hereof shall survive the termination of this Agreement. 

SECTION 8. Expenses. All fees and expenses incurred in connection this Agreement and the transactions contemplated hereby shall be paid
by the party incurring such fees or expenses, whether or not the Offer or the Merger is consummated. 
 SECTION 9. Public
Announcements. The Stockholder, on behalf of itself and each other Subject Stockholder, consents to and authorizes the publication and disclosure by the Company of each Subject Stockholder’s identity and ownership of the Shares and the
existence and terms of this Agreement (including, for the avoidance of 

  
 5 

 
doubt, the disclosure of this Agreement) and any other information, in each case, in any press release, any Current Report on Form 8-K, the Offer Documents, the Form S-4, and any other disclosure
document in connection with the Merger Agreement; provided, that the Company shall provide the Stockholder with the opportunity to review and comment upon such publication or disclosure prior to its release. Parent and Purchaser hereby consent to
and authorize the publication and disclosure by the Stockholder of the existence and terms of this Agreement (including, for the avoidance of doubt, the disclosure of this Agreement) and any other information, in each case, that the Stockholder
reasonably determines in its good faith judgment is required to be disclosed by Law, including in any Schedule 13D/A filing. 
 SECTION 10.
Adjustments. In the event that, between the date of this Agreement and the Effective Time, (a) the number of issued and outstanding Shares or securities convertible or exchangeable into or exercisable for Shares changes as a result of a
reclassification, stock split (including a reverse stock split), stock dividend or distribution, recapitalization, merger, issuer tender or exchange offer, or other similar transaction, or (b) each Subject Stockholder shall become the
beneficial owner of any additional shares of Company Common Stock, then the terms of this Agreement shall apply to the shares of Company Common Stock held by such Subject Stockholder immediately following the effectiveness of the events described in
clause (a) or such Subject Stockholder becoming the beneficial owners thereof as described in clause (b), as though, in either case, they were Shares hereunder. 

SECTION 11. Miscellaneous. 

(a) Certain Definitions. Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to such terms in the
Merger Agreement. 
 (b) Notices. All notices and other communications hereunder shall be in writing and shall be deemed given if
delivered personally (notice deemed given upon receipt), telecopied (notice deemed given upon confirmation of receipt) or sent by a nationally recognized overnight courier service, such as Federal Express (notice deemed given upon receipt of proof
of delivery), to the parties at the following addresses (or at such other address for a party as shall be specified by like notice): 
 If
to the Stockholder or any Subject Stockholder, to: 
 Robert W. Duggan 

c/o Pharmacyclics, Inc. 
 995 E.
Arques Avenue 
 Sunnyvale, California 94085-4521 

Facsimile: (408) 774-0340 

  
 6 

 with a copy to: 

Wilson Sonsini Goodrich & Rosati P.C. 

One Market Plaza, Spear Tower, Suite 3300 

San Francisco, CA 94105 

Attention: Robert T. Ishii and Denny Kwon 

Facsimile: (415) 947-2099 

If to Parent or Purchaser, to: 

AbbVie Inc. 
 1 North Waukegan
Road 
 North Chicago, Illinois 60064-6400 

Attention: Laura J. Schumacher, Executive Vice President, 

Business Development, External Affairs and General 

Counsel 

Facsimile: (847) 935-3294 

and with a copy to: 

Wachtell, Lipton, Rosen & Katz 

51 West 52nd Street 
 New York,
New York 10019 
 Attention: Edward D. Herlihy 

David C. Karp 

David K. Lam 

Facsimile: (212) 403-2000 

(c) Headings. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement. 
 (d) Counterparts. This Agreement may be executed manually or by facsimile by the parties, in
any number of counterparts, each of which shall be considered one and the same agreement and shall become effective when a counterpart hereof shall have been signed by each of the parties and delivered to the other parties. 

(e) Entire Agreement, No Third-Party Beneficiaries. This Agreement constitutes the entire agreement among the parties with respect to
the subject matter hereof and thereof and supersedes all other prior agreements and understandings, both written and oral, among the parties or any of them with respect to the subject matter hereof and thereof. This Agreement is not intended to
confer upon any Person other than the parties hereto any rights or remedies hereunder. 
 (f) Governing Law and Venue; Waiver of Jury
Trial; Specific Performance. 

  
 7 

 (i) This Agreement shall be governed by, and construed in accordance with, the laws of the State
of Delaware, without giving effect to conflicts of laws principles that would result in the application of the Law of any other state. 

(ii) Each of the parties hereto hereby irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of
the Court of Chancery of the State of Delaware, or, if (and only if) such court finds it lacks subject matter jurisdiction, the Federal court of the United States of America sitting in Delaware, and any appellate court from any thereof, in any
action or proceeding arising out of or relating to this Agreement or the agreements delivered in connection herewith or the transactions contemplated hereby or thereby or for recognition or enforcement of any judgment relating thereto, and each of
the parties hereby irrevocably and unconditionally (A) agrees not to commence any such action or proceeding except in the Court of Chancery of the State of Delaware, or, if (and only if) such court finds it lacks subject matter jurisdiction,
the Federal court of the United States of America sitting in Delaware, and any appellate court from any thereof, (B) agrees that any claim in respect of any such action or proceeding may be heard and determined in the Court of Chancery of the
State of Delaware, or, if (and only if) such court finds it lacks subject matter jurisdiction, the Federal court of the United States of America sitting in Delaware, and any appellate court from any thereof, (C) waives, to the fullest extent it
may legally and effectively do so, any objection that it may now or hereafter have to the laying of venue of any such action or proceeding in such courts and (D) waives, to the fullest extent permitted by Law, the defense of an inconvenient
forum to the maintenance of such action or proceeding in such courts. Each of the Parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or
in any other manner provided by Law. Each Party to this Agreement irrevocably consents to service of process inside or outside the territorial jurisdiction of the courts referred to in this Section 11(f) in the manner provided for
notices in Section 11(b). Nothing in this Agreement will affect the right of any Party to this Agreement to serve process in any other manner permitted by Law. 

(iii) EACH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY
OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT AND OTHER TRANSACTIONS CONTEMPLATED HEREBY . EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR
OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE EITHER OF SUCH WAIVERS, (B) IT UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF SUCH WAIVERS, (C) IT MAKES SUCH WAIVERS VOLUNTARILY, AND (D) IT
HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 12(F). 

(iv) The parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed by

  
 8 

 
any party in accordance with their specific terms or were otherwise breached by such party. It is accordingly agreed that, prior to the termination of this Agreement pursuant to
Section 7, the non-breaching party shall be entitled to an injunction or injunctions to prevent breaches of this Agreement by the other party and to enforce specifically the terms and provisions of this Agreement against the other party,
this being in addition to any other remedy to which such party is entitled at law or in equity, and each party hereby waives any requirement for the posting of any bond or similar collateral in connection therewith. Prior to the termination of this
Agreement pursuant to Section 7, each party hereby agrees that it will not oppose the granting of an injunction, specific performance and other equitable relief on the basis that (i) the other party has an adequate remedy at law or
(ii) an award of specific performance is not an appropriate remedy for any reason at law or in equity. 
 (g) Assignment. This
Agreement shall not be assigned by any of the parties hereto (whether by operation of Law or otherwise) without the prior written consent of the other parties. Subject to the preceding sentence, but without relieving any party hereto of any
obligation hereunder, this Agreement will be binding upon, inure to the benefit of and be enforceable by the parties hereto and their respective successors and assigns. 

(h) Severability of Provisions. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by
rule of Law or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the
parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties hereto as closely as possible in an acceptable manner. 

(i) Modification or Amendment. Subject to applicable Law and except as otherwise provided in this Agreement, this Agreement may be
amended, modified and supplemented by written agreement of the parties hereto. This Agreement may not be amended except by an instrument in writing signed on behalf of each of the parties hereto. 

(k) No Recourse. Parent and Purchaser agree that no Subject Stockholder (in his capacity as a stockholder of the Company) will be
liable for claims, losses, damages, liabilities or other obligations resulting from the Company’s breach of the Merger Agreement. 

(l) No Ownership Interest. Except as otherwise provided herein, nothing contained in this Agreement shall be deemed to vest in Parent
any direct or indirect ownership or incidence of ownership of or with respect to the Shares. All rights, ownership and economic benefits of and relating to the Shares shall remain vested in and belong to the Subject Stockholders, and Parent shall
have no authority to manage, direct, restrict, regulate, govern, or administer any of the policies or operations of the Company or exercise any power or authority to direct any Subject Stockholder in the voting of any of the Shares, except as
otherwise provided herein. 

  
 9 

 [REMAINDER OF PAGE LEFT BLANK INTENTIONALLY] 

  
 10 

 IN WITNESS WHEREOF, Parent, Purchaser and the Stockholder have caused this Agreement to be duly
executed and delivered as of the date first written above. 
  

			
	ABBVIE INC.
		
	By:		 /s/ William J. Chase

			Name: William J. Chase
			Title: Chief Financial Officer and Executive Vice President
	
	OXFORD AMHERST CORPORATION
		
	By:		 /s/ William J. Chase

			Name: William J. Chase
			Title: President
	
	THE STOCKHOLDER:
		
	By:		 /s/ Robert W. Duggan

			Name: Robert W. Duggan

 SCHEDULE I 
  

																													
	 Name and Address
	  	Company
Common Stock	 	  	Vested
Options	 	  	Unvested
Options	 	  	Restricted
Stock	 	  	Performance
Based Stock
Units	 	  	Deferred
Stock
Units	 	  	Warrants	 
	 Robert W. Duggan

c/o Pharmacyclics, Inc.

995 E. Arques Avenue

Sunnyvale, California 94085-4521

Facsimile: (408) 774-0340
	  	 	11,844,210	  	  	 	0	  	  	 	0	  	  	 	0	  	  	 	0	  	  	 	0	  	  	 	0	  
	 Patricia J Duggan

c/o Pharmacyclics, Inc.

995 E. Arques Avenue

Sunnyvale, California 94085-4521

Attention: Robert W. Duggan

Facsimile: (408) 774-0340
	  	 	1,020,756	  	  	 	0	  	  	 	0	  	  	 	0	  	  	 	0	  	  	 	0	  	  	 	0	  
	 Blazon Corp.

c/o Pharmacyclics, Inc.

995 E. Arques Avenue

Sunnyvale, California 94085-4521

Attention: Robert W. Duggan

Facsimile: (408) 774-0340
	  	 	5,421	  	  	 	0	  	  	 	0	  	  	 	0	  	  	 	0	  	  	 	0	  	  	 	0	  
	 Multiaccess Computing Corp.

c/o Pharmacyclics, Inc.

995 E. Arques Avenue

Sunnyvale, California 94085-4521

Attention: Robert W. Duggan

Facsimile: (408) 774-0340
	  	 	308,784	  	  	 	0	  	  	 	0	  	  	 	0	  	  	 	0	  	  	 	0	  	  	 	0	  
								
	 Total:
	  	 	13,179,171	  	  	 	0	  	  	 	0	  	  	 	0	  	  	 	0	  	  	 	0	  	  	 	0EX-10.2

 Exhibit 10.2 

PHARMACYCLICS, INC. 

CHANGE IN CONTROL AND SEVERANCE PLAN 

AND SUMMARY PLAN DESCRIPTION 

Effective as of March 4, 2015 

1. Introduction. The purpose of this Pharmacyclics, Inc. Change in Control and Severance Plan (the “Plan”) is
to provide assurances of specified benefits to eligible employees of the Company and its Subsidiaries and Affiliates in the event their employment is involuntarily terminated other than for death, Disability, or Cause or voluntarily terminated for
Good Reason under the circumstances described in the Plan. This Plan is an “employee welfare benefit plan,” as defined in Section 3(1) of ERISA. This Plan is governed by ERISA and, to the extent applicable, the laws of the
State of California. This document constitutes both the written instrument under which the Plan is maintained and the required summary plan description for the Plan. 

2. Important Terms. The following words and phrases, when the initial letter of the term is capitalized, will have the meanings
set forth in this Section 2, unless a different meaning is plainly required by the context: 
 2.1.
“Administrator” means the Company, acting through the Compensation Committee or another duly constituted committee of members of the Board, or any person to whom the Administrator has delegated any authority or responsibility with
respect to the Plan pursuant to Section 10, but only to the extent of such delegation. 
 2.2.
“Affiliate” means, as of any time, the Company and any other person with whom the Company would be considered a single employer under Sections 414(b) or 414(c) of the Code, as determined applying the rules of
Section 1.409A-1(h)(3) of the Treasury Regulations, such that any such person would constitute an “employer” or “service recipient” under such Section 1.409A-1(h)(3) with respect
to an Eligible Employee and an Eligible Employee’s severance rights under this Agreement, except that the language “at least seventy-nine percent” is used at each place it appears in Section 1563(a)(1), (2) and (3) of
the Code and in Section 1.414(c)-2 of the Treasury Regulations. 
 2.3. “Agreement” means that certain
Agreement and Plan of Reorganization by and among AbbVie Inc., a Delaware corporation, the Company, and certain other parties, dated March 4, 2015. 

2.4. “Base Pay” means the higher of: (a)an Eligible Employee’s annualized base salary in effect immediately prior
to the Change in Control or (b) such Eligible Employee’s annualized base salary in effect immediately prior to his or her termination of employment (or if the termination is due to a resignation for Good Reason based on a material
reduction in base pay, then the Eligible Employee’s annualized base salary in effect immediately prior to such reduction). 

2.5. “Board” means the Board of Directors of the Company. 

  

 2.6. “Cause” means, with respect to any Eligible Employee,
the occurrence of any of the following: (a) the Eligible Employee’s conviction of, or plea of nolo contendere to, a felony or any crime involving fraud or embezzlement that has had or will have a material detrimental effect on the
Company’s reputation or business, (b) the Eligible Employee’s willful and intentional gross misconduct that has had or will have a material detrimental effect on the Company’s reputation or business, (c) the Eligible
Employee’s unauthorized use or disclosure of any proprietary information or trade secrets of the Company that has had or will have a material detrimental effect on the Company’s reputation or business, or (d) the Eligible
Employee’s willful and intentional breach of material obligations under a written agreement or covenant with the Company that has had or will have a material detrimental effect on the Company’s reputation or business. Notwithstanding the
preceding sentence, the Company’s termination of an Eligible Employee’s employment will not be treated as for “Cause” unless the Company first provides the Eligible Employee with written notice specifically identifying the acts
or omissions constituting the grounds for a termination for “Cause” and, with respect to clauses (b) through (d), a reasonable cure period of not less than 10 business days following such notice. For purposes of this definition,
no act or failure to act by an Eligible Employee will be considered “willful” unless committed without good faith and without a reasonable belief that the act or omission was in the Company’s best interest. 

2.7. “Change in Control” means the completion of the transactions contemplated by the Agreement, which will qualify as a
“change in control event” within the meaning of Code Section 409A. 
 2.8. “Change in Control Period”
means the time period beginning on the Change in Control and ending 24 months following the Change in Control. 
 2.9.
“Code” means the Internal Revenue Code of 1986, as amended. 
 2.10. “Company” means
Pharmacyclics, Inc., a Delaware corporation, and any successor that assumes the obligations of the Company under the Plan, by way of merger, acquisition, consolidation or other transaction. 

2.11. “Compensation Committee” means the Compensation Committee of the Board.  

2.12. “Eligible Employee” means an individual who is an employee of the Company or any Subsidiary or Affiliate of the
Company as of immediately before the Change in Control. 
 2.13. “Disability”means that the Eligible Employee
has been unable to perform the Eligible Employee’s Company duties as the result of the Eligible Employee’s incapacity due to physical or mental illness, and such inability, at least 26 weeks after its commencement or 180 days in any
consecutive 12-month period, is determined to be total and permanent by a physician selected by the Company or its insurers and acceptable to the Eligible Employee or the Eligible Employee’s legal representative (such agreement as to
acceptability not to be unreasonably withheld). Termination resulting from Disability may only be effected after at least 30 days’ written notice by the Company of its intention to terminate the Eligible Employee’s employment. 

  
 - 2 - 

 
In the event that the Eligible Employee resumes the performance of substantially all of the Eligible Employee’s duties hereunder before the termination of the Eligible Employee’s
employment becomes effective, the notice of intent to terminate will automatically be deemed to have been revoked. 
 2.14.
“Effective Date” means March 4, 2015. 
 2.15. “ERISA” means the Employee Retirement Income Security
Act of 1974, as amended. 
 2.16. “Good Reason” means the occurrence of one or more of the following without an Eligible
Employee’s express written consent: (a) a material adverse alteration in the Eligible Employee’s position or in the nature or status of the Eligible Employee’s duties and responsibilities from those in effect immediately prior to
the Change in Control; provided, however, that the continued employment of an Eligible Employee following the Change in Control with substantially the same duties and responsibilities with respect to the Company’s business and operations, or an
alteration in duties and responsibilities as a result of the Company no longer being a publicly traded company, but rather a Subsidiary or business unit of the acquirer, will not constitute “Good Reason”, (b) any reduction in the
Eligible Employee’s base salary rate or target annual bonus, in each case as in effect immediately prior to the Change in Control, or (c) the relocation of the Eligible Employee’s principal place of employment to a location that is
more than 50 miles from the location where the Eligible Employee was principally employed at the time of the Change in Control or materially increases the time of the Eligible Employee’s commute as compared to the Eligible Employee’s
commute at the time of the Change in Control (except for required travel on the Company’s business to an extent substantially consistent with the Eligible Employee’s customary business travel obligations in the ordinary course of business
prior to the Change in Control). In order for an Eligible Employee’s termination to be for “Good Reason,” the Eligible Employee must first provide the Company with written notice of the acts or omissions constituting the grounds for
“Good Reason” within 90 days following the Eligible Employee’s knowledge of the initial existence of the grounds for “Good Reason” specifying in reasonable detail the conditions constituting Good Reason and a reasonable cure
period of 30 days following the date of written notice (the “Cure Period”), such grounds must not have been cured during the Cure Period, and the Eligible Employee must resign within 2 years following the end of the Cure Period.

 2.17. “Involuntary Termination” means (a) a termination of active employment with the Company or any Subsidiary or
Affiliate of the Company for any reason other than by reason of an Eligible Employee’s retirement (prior to his Involuntary Termination or resignation for Good Reason), voluntary resignation, death or Disability, or a termination for Cause.

 2.18. “Parent” means a “parent corporation,” whether now or hereafter existing, as defined in
Code Section 424(e). 
 2.19. “Plan” means the Pharmacyclics, Inc. Change in Control and Severance Plan, as set forth
in this document, and as hereafter amended from time to time. 

  
 - 3 - 

 2.20. “Section 409A Limit” means two times the lesser of: (a) the
Eligible Employee’s annualized compensation based upon the annual rate of pay paid to the Eligible Employee during the Eligible Employee’s taxable year preceding the Eligible Employee’s taxable year of the Eligible Employee’s
termination of employment as determined under, and with such adjustments as are set forth in, Treasury Regulation 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with respect thereto; or (b) the maximum amount that
may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Code for the year in which the Eligible Employee’s employment is terminated. 

2.21. “Severance Benefits” means the compensation and other benefits that the Eligible Employee will be provided in
the circumstances described in Section 3. 
 2.22. “Subsidiary” means a
“subsidiary corporation,” whether now or hereafter existing, as defined in Code Section 424(f). 
 2.23.
“Target Bonus” means higher of: (a) an Eligible Employee’s target annual bonus in effect immediately prior to the Change in Control or (b) such Eligible Employee’s target annual bonus in effect immediately prior
to his or her termination of employment (or if the termination is due to a resignation for Good Reason based on a material reduction in target annual bonus, then the Eligible Employee’s target annual bonus in effect immediately prior to such
reduction). 
 3. Involuntary Termination or Resignation for Good Reason During the Change in Control Period. If,
during the Change in Control Period, an Eligible Employee’s employment with the Company or any Subsidiary or Affiliate of the Company terminates due to an Involuntary Termination or resignation for Good Reason, then, subject to the Eligible
Employee’s compliance with Section 5, the Eligible Employee will receive the following Severance Benefits from the Company: 

3.1. Cash Severance Benefits. A lump-sum payment of cash severance in an aggregate amount equal to the sum of: (a) 100% of
the Eligible Employee’s Base Pay and (b) 100% of the Eligible Employee’s Target Bonus. 
 3.2. Continued
Medical Benefits. If the Eligible Employee and any spouse and/or dependents of the Eligible Employee (“Family Members”) have coverage on the date of the Eligible Employee’s Involuntary Termination or resignation for Good
Reason under a group health plan sponsored by the Company, the Company will reimburse the Eligible Employee the total applicable premium cost for continued group health plan coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985,
as amended (“COBRA”) during the 12-month period following the termination of Eligible Employee’s employment, provided that the Eligible Employee validly elects and is eligible to continue coverage under COBRA for the Eligible
Employee and his Family Members. However, if the Company determines in its sole discretion that it cannot provide the COBRA reimbursement benefits without potentially violating applicable laws (including, without limitation, Section 2716 of the
Public Health Service Act and the Eligible Employee Retirement Income Security Act of 1974, as amended), the Company will in lieu thereof provide to the Eligible Employee a taxable monthly payment in an amount equal to the monthly COBRA premium that
the Eligible Employee would be required to pay to  

  
 - 4 - 

 
continue the group health coverage in effect on the date of the Eligible Employee’s termination of employment (which amount will be based on the premium for the first month of COBRA
coverage) for the 12-month period following the termination of Eligible Employee’s employment, which payments will be made regardless of whether the Eligible Employee elects COBRA continuation coverage. 

4. Tax Gross-Up. In the event an Eligible Employee becomes entitled to any amounts or benefits payable in connection with a
Change in Control, including the value of accelerated vesting of equity (and whether or not such amounts are payable pursuant to this Plan) (the “Change in Control Payments”), if any of such Change in Control Payments are subject to
the tax imposed by Section 4999 of the Code or any similar federal, state or local tax that may hereafter be imposed (the “Excise Tax”), the Company shall pay the Eligible Employee at the time specified in clause (c) below
an additional amount (the “Gross-Up Payment”) such that the net amount retained by the Eligible Employee after payment of any Excise Tax on the Change in Control Payments and any federal, state and local income or employment tax and
Excise Tax upon the Gross-Up Payment provided for by this Section 4 shall be equal to the net amount the Eligible Employee would have retained after payment of any federal, state and local income or employment tax on the Change in Control
Payments had the Change in Control Payments not been subject to the Excise Tax. 
 4.1. All determinations under this Section 4
shall be made at the expense of the Company by a nationally recognized tax counsel, public accounting firm or compensation consultant selected by the Company and subject to the Eligible Employee’s approval, which approval shall not be
unreasonably withheld. Such determinations shall be binding upon the Eligible Employee and the Company. 
 4.2. For purposes of
determining the amount of the Gross-Up Payment, the Eligible Employee shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation in the calendar year in which the Gross-Up Payment is to be made and state and
local income taxes at the Eligible Employee’s marginal rate of taxation in the state and locality of his residence on the date of the Change in Control, net of the maximum reduction in federal income taxes which could be obtained from deduction
of such state and local taxes. 
 4.3. The Gross-Up Payment provided for in this Section 4 shall be made to the Eligible Employee at
least 30 days prior to such time as he or she is required to remit the taxes described above to the applicable taxing authorities; provided, however, that if the amount of the Gross-Up Payment cannot be finally determined on or before the 30th day prior to the date the taxes are due, the Company shall pay the Eligible Employee on such day an estimate, as determined in good faith by the Company, of the minimum amount of the Gross-Up
Payment (the “Estimated Payment”) and shall pay the remainder of the Gross-Up Payment (together with interest at the rate provided in Section 1274(b)(2)(B) of the Code) as soon as the amount thereof can be determined. In
the event that the amount of the Estimated Payment exceeds the amount of the Gross-Up Payment, the Eligible Employee shall repay such excess to the Company within 15 days after demand by the Company. 

  
 - 5 - 

 5. Conditions to Receipt of Severance. 

5.1. Release Agreement. As a condition to receiving the Severance Benefits under this Plan, each Eligible Employee will be
required to sign and not revoke the separation and release of claims agreement attached to this Plan as Exhibit B (the “Release”). In all cases, the Release must become effective and irrevocable no later than the 60th day following the Eligible Employee’s Involuntary Termination or resignation for Good Reason (the “Release Deadline Date”). If the Release does not become effective and
irrevocable by the Release Deadline Date, the Eligible Employee will forfeit any right to the Severance Benefits. In no event will the Severance Benefits be paid or provided until the Release becomes effective and irrevocable.  

5.2. Other Requirements. An Eligible Employee’s receipt of Severance Benefits will be subject to the Eligible Employee
continuing to comply with the provisions of this Section 5 and the terms of any confidentiality, proprietary information and inventions agreement and such other appropriate agreement between the Eligible Employee and the Company. Severance
Benefits under this Plan will terminate immediately for an Eligible Employee if the Eligible Employee, at any time, violates any such agreement and/or the provisions of this Section 5. 

6. Timing of Severance Benefits. Provided that the Release becomes effective and irrevocable by the Release Deadline Date and
subject to Section 8, the severance payments and benefits under this Plan will be paid, or in the case of installments, will commence, on the Release Deadline Date (such payment date, the “Severance Start Date”), and any
severance payments or benefits otherwise payable to the Eligible Employee during the period immediately following the Eligible Employee’s termination of employment with the Company or any Subsidiary or Affiliate of the Company through the
Severance Start Date will be paid in a lump sum to the Eligible Employee on the Severance Start Date, with any remaining payments to be made as provided in this Plan.  

7. Non-Duplication of Benefits. Notwithstanding any other provision in the Plan to the contrary, if the Eligible Employee is
entitled to any severance, change in control or similar benefits outside of the Plan by operation of applicable law or under another Company-sponsored plan, policy, contract, or arrangement, his or her benefits under the Plan will be reduced by the
value of the severance, change in control or similar benefits that the Eligible Employee receives by operation of applicable law or under any Company-sponsored plan, policy, contract, or arrangement, all as determined by the Administrator in its
discretion. 
 8. Section 409A. 

8.1. Notwithstanding anything to the contrary in this Plan, no severance payments or benefits to be paid or provided to an Eligible
Employee, if any, under this Plan that, when considered together with any other severance payments or separation benefits, are considered deferred compensation under Section 409A of the Code, and the final regulations and any guidance
promulgated thereunder (“Section 409A”) (together, the “Deferred Payments”) will be paid or provided until the Eligible Employee has a “separation from service” within the meaning of Section 409A.
Similarly, no severance payable to an Eligible Employee, if any,  

  
 - 6 - 

 
under this Plan that otherwise would be exempt from Section 409A pursuant to Treasury Regulation Section 1.409A-1(b)(9) will be payable until the
Eligible Employee has a “separation from service” within the meaning of Section 409A. 
 8.2. It is intended that none of the
severance payments or benefits under this Plan will constitute Deferred Payments but rather will be exempt from Section 409A as a payment that would fall within the “short-term deferral period” as described in Section 9.4 below
or resulting from an involuntary separation from service as described in Section 8.5 below. In no event will an Eligible Employee have discretion to determine the taxable year of payment of any Deferred Payment. 

8.3. Notwithstanding anything to the contrary in this Plan, if an Eligible Employee is a “specified employee” within the meaning of
Section 409A at the time of the Eligible Employee’s separation from service (other than due to death), then the Deferred Payments, if any, that are payable within the first six months following the Eligible Employee’s separation from
service, will become payable on the date six months and one day following the date of the Eligible Employee’s separation from service. All subsequent Deferred Payments, if any, will be payable in accordance with the payment schedule applicable
to each payment or benefit. Notwithstanding anything herein to the contrary, in the event of the Eligible Employee’s death following the Eligible Employee’s separation from service, but before the six month anniversary of the separation
from service, then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of the Eligible Employee’s death and all other Deferred Payments will be payable in
accordance with the payment schedule applicable to each payment or benefit. Each payment and benefit payable under this Plan is intended to constitute a separate payment under Section 1.409A-2(b)(2) of the Treasury Regulations. 

8.4. Any amount paid under this Plan that satisfies the requirements of the “short-term deferral” rule set forth in
Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Payments for purposes of Section 8.1 above. 

8.5. Any amount paid under this Plan that qualifies as a payment made as a result of an involuntary separation from service pursuant to
Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A Limit will not constitute Deferred Payments for purposes of Section 8.1 above. 

8.6. The foregoing provisions are intended to comply with or be exempt from the requirements of Section 409A so that none of the payments
and benefits to be provided under the Plan will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply or be exempt. Notwithstanding anything to the contrary in the Plan,
including but not limited to Sections 10 and 13, the Company reserves the right to amend the Plan as it deems necessary or advisable, in its sole discretion and without the consent of the Eligible Employees, to comply with Section 409A or
to avoid income recognition under Section 409A prior to the actual payment of benefits under the Plan or imposition of any additional tax. In no event will the Company reimburse an Eligible Employee for any taxes that may be imposed on the
Eligible Employee as result of Section 409A. 

  
 - 7 - 

 9. Withholdings. The Company will withhold from any payments or benefits under the
Plan all applicable U.S. federal, state, local and non-U.S. taxes required to be withheld and any other required payroll deductions. 

10. Administration. The Company is the administrator of the Plan (within the meaning of section 3(16)(A) of
ERISA). The Plan will be administered and interpreted by the Administrator (in his or her sole discretion). The Administrator is the “named fiduciary” of the Plan for purposes of ERISA and will be subject to the
fiduciary standards of ERISA when acting in such capacity. Any decision made or other action taken by the Administrator with respect to the Plan, and any interpretation by the Administrator of any term or condition of the Plan, or any related
document, will be conclusive and binding on all persons and be given the maximum possible deference allowed by law. In accordance with Section 2.1, the Administrator (a) may, in its sole discretion and on such terms and conditions as it
may provide, delegate in writing to one or more officers of the Company all or any portion of its authority or responsibility with respect to the Plan, and (b) has the authority to act for the Company (in a non-fiduciary capacity) as to any
matter pertaining to the Plan; provided, however, that any Plan amendment or termination or any other action that reasonably could be expected to increase materially the cost of the Plan must be approved by the Board. 

11. Eligibility to Participate. To the extent that the Administrator has delegated administrative authority or responsibility to one or
more officers of the Company in accordance with Sections 2.1 and 10, each such officer will not be excluded from participating in the Plan if otherwise eligible, but he or she is not entitled to act upon or make determinations regarding any
matters pertaining specifically to his or her own benefit or eligibility under the Plan. The Administrator will act upon and make determinations regarding any matters pertaining specifically to the benefit or eligibility of each such officer under
the Plan. 
 12. Term. The Plan will become effective upon the Effective Date and will terminate automatically upon the
completion of all payments (if any) under the terms of the Plan.  
 13. Amendment or Termination. The Company, by
action of the Administrator, reserves the right to amend or terminate the Plan at any time, without advance notice to any Eligible Employee and without regard to the effect of the amendment or termination on any Eligible Employee or on any other
individual. Any amendment or termination of the Plan will be in writing. Notwithstanding the foregoing, any amendment to the Plan that (a) causes an individual or group of individuals to cease to be eligible for the Severance Benefits under the
Plan or (b) reduces or alters to the detriment of the Eligible Employee the Severance Benefits potentially payable to that Eligible Employee (including, without limitation, imposing additional conditions or modifying the timing of payment),
will not be effective unless it both is approved by the Administrator and communicated to the affected individual(s) in writing at least six months prior to the effective date of the amendment or termination and once an Eligible Employee has
incurred an Involuntary Termination or has resigned for Good Reason, no amendment or termination of the Plan may, without that Eligible Employee’s written consent, reduce or alter to the detriment of the Eligible Employee, the Severance
Benefits payable to that Eligible Employee. In addition, notwithstanding the preceding, upon or after a Change in Control, the Company may not, without an Eligible Employee’s written consent, amend or terminate the Plan in any way, nor take any
other action, that (a) prevents that Eligible Employee 

  
 - 8 - 

 
from becoming eligible for the Severance Benefits under the Plan, or (b) reduces or alters to the detriment of the Eligible Employee the Severance Benefits payable, or potentially payable,
to an Eligible Employee under the Plan (including, without limitation, imposing additional conditions). Any action of the Company in amending or terminating the Plan will be taken in a non-fiduciary capacity.

 14. Claims and Appeals. 

14.1. Claims Procedure. Any employee or other person who believes he or she is entitled to any payment under the Plan may submit
a claim in writing to the Administrator within 90 days of the earlier of (a) the date the claimant learned the amount of his or her benefits under the Plan or (b) the date the claimant learned that he or she will not be entitled to
any benefits under the Plan. If the claim is denied (in full or in part), the claimant will be provided a written notice explaining the specific reasons for the denial and referring to the provisions of the Plan on which the denial is based. The
notice also will describe any additional information needed to support the claim and the Plan’s procedures for appealing the denial. The denial notice will be provided within 90 days after the claim is received. If special circumstances require
an extension of time (up to 90 days), written notice of the extension will be given within the initial 90-day period. This notice of extension will indicate the special circumstances requiring the extension of time and the date by which the
Administrator expects to render its decision on the claim. 
 14.2. Appeal Procedure. If the claimant’s claim is
denied, the claimant (or his or her authorized representative) may apply in writing to the Administrator for a review of the decision denying the claim. Review must be requested within 60 days following the date the claimant received the written
notice of their claim denial or else the claimant loses the right to review. The claimant (or representative) then has the right to review and obtain copies of all documents and other information relevant to the claim, upon request and at no charge,
and to submit issues and comments in writing. The Administrator will provide written notice of its decision on review within 60 days after it receives a review request. If additional time (up to 60 days) is needed to review the request, the claimant
(or representative) will be given written notice of the reason for the delay. This notice of extension will indicate the special circumstances requiring the extension of time and the date by which the Administrator expects to render its decision. If
the claim is denied (in full or in part), the claimant will be provided a written notice explaining the specific reasons for the denial and referring to the provisions of the Plan on which the denial is based. The notice also will include a
statement that the claimant will be provided, upon request and free of charge, reasonable access to, and copies of, all documents and other information relevant to the claim and a statement regarding the claimant’s right to bring an action
under Section 502(a) of ERISA. 
 15. Attorneys’ Fees. The parties shall each bear their own expenses, legal
fees and other fees incurred in connection with this Plan. Provided, however, in the event that an Eligible Employee is required to incur attorneys’ fees in order to obtain any payments or benefits under this Plan, and provided that the
Eligible Employee prevails on at least one material issue related to his or her claim(s) under the Plan, then the Company will reimburse the attorneys’ fees incurred by the Eligible Employee. The reimbursements will be made in accordance with
the Company’s normal reimbursement policies following final adjudication of the Eligible  

  
 - 9 - 

 
Employee’s claims, provided however, that (a) the reimbursements are payable only during the Eligible Employee’s lifetime, (b) the reimbursements will be made on or before the
last day of the Eligible Employee’s taxable year following the taxable year in which the expenses were incurred, (c) the right to reimbursement, if any, is not subject to liquidation or exchange for another benefit, and (d) the amount
of expenses eligible for reimbursement during an Eligible Employee’s taxable year will not affect the expenses eligible for reimbursement to be provided in any other taxable year. 

16. Source of Payments. All Severance Benefits will be paid in cash from the general funds of the Company; no separate fund will
be established under the Plan, and the Plan will have no assets. No right of any person to receive any payment under the Plan will be any greater than the right of any other general unsecured creditor of the Company. 

17. Inalienability. In no event may any Eligible Employee sell, transfer, anticipate, assign or otherwise dispose of any right
or interest under the Plan. At no time will any such right or interest be subject to the claims of creditors nor liable to attachment, execution or other legal process. 

18. No Enlargement of Employment Rights. Neither the establishment or maintenance or amendment of the Plan, nor the making of
any benefit payment hereunder, will be construed to confer upon any individual any right to continue to be an employee of the Company. The Company expressly reserves the right to discharge any of its employees at any time, with or without cause.
However, as described in the Plan, an Eligible Employee may be entitled to benefits under the Plan depending upon the circumstances of his or her termination of employment. 

19. Successors. Any successor to the Company of all or substantially all of the Company’s business or assets (whether
direct or indirect and whether by purchase, merger, consolidation, liquidation or other transaction) will assume the obligations under the Plan and agree expressly to perform the obligations under the Plan in the same manner and to the same extent
as the Company would be required to perform such obligations in the absence of a succession. For all purposes under the Plan, the term “Company” will include any successor to the Company’s business and/or assets which become bound by
the terms of the Plan by operation of law, or otherwise. 
 20. Applicable Law. The provisions of the Plan will be
construed, administered and enforced in accordance with ERISA and, to the extent applicable, the internal substantive laws of the state of California (but not its conflict of laws provisions). 

21. Severability. If any provision of the Plan is held invalid or unenforceable, its invalidity or unenforceability will not
affect any other provision of the Plan, and the Plan will be construed and enforced as if such provision had not been included. 

22. Headings. Headings in this Plan document are for purposes of reference only and will not limit or otherwise affect the
meaning hereof. 
 23. Indemnification. The Company hereby agrees to indemnify and hold harmless the officers and
employees of the Company, and the members of its Board, from all losses,  

  
 - 10 - 

 
claims, costs or other liabilities arising from their acts or omissions in connection with the administration, amendment or termination of the Plan, to the maximum extent permitted by applicable
law. This indemnity will cover all such liabilities, including judgments, settlements and costs of defense. The Company will provide this indemnity from its own funds to the extent that insurance does not cover such liabilities. This indemnity is in
addition to and not in lieu of any other indemnity provided to such person by the Company. 
 24. Additional Information. 

 

			
	Plan Name:		Pharmacyclics, Inc. Change in Control and Severance Plan
		
	Plan Sponsor:		Pharmacyclics, Inc.
			995 E. Arques Avenue
			Sunnyvale, CA 94085-4521
		
	Identification Numbers:		EIN: 94-3148201
			PLAN: [NUMBER]
		
	Plan Year:		Company’s fiscal year
		
	Plan Administrator:		Pharmacyclics, Inc.
			Attention: Administrator of the Pharmacyclics, Inc.
			Change in Control and Severance Plan
			995 E. Arques Avenue
			Sunnyvale, CA 94085-4521
			(408) 774-0330
		
	Agent for Service of		
	Legal Process:		Pharmacyclics, Inc.
			995 E. Arques Avenue
			Sunnyvale, CA 94085-4521
			(408) 774-0330
		
			Service of process also may be made upon the Administrator.
		
	Type of Plan		Severance Plan/Employee Welfare Benefit Plan
		
	Plan Costs		The cost of the Plan is paid by the Employer.

  
 - 11 - 

 25. Statement of ERISA Rights. 

As an Eligible Employee eligible to participate in the Plan, you have certain rights and protections under ERISA: 

(a) You may examine (without charge) all Plan documents, including any amendments and copies of all documents filed with the U.S. Department
of Labor. These documents are available for your review in the Company’s Human Resources Department. 
 (b) You may obtain copies of
all Plan documents and other Plan information upon written request to the Administrator. A reasonable charge may be made for such copies. 

In addition to creating rights for Eligible Employees, ERISA imposes duties upon the people who are responsible for the operation of the Plan.
The people who operate the Plan (called “fiduciaries”) have a duty to do so prudently and in the interests of you and the other Eligible Employees. No one, including the Company or any other person, may fire you or otherwise
discriminate against you in any way to prevent you from obtaining a benefit under the Plan or exercising your rights under ERISA. If your claim for a severance benefit is denied, in whole or in part, you must receive a written explanation of the
reason for the denial. You have the right to have the denial of your claim reviewed. (The claim review procedure is explained in Section 14 above.) 

Under ERISA, there are steps you can take to enforce the above rights. For example, if you request materials and do not receive them within 30
days, you may file suit in a federal court. In such a case, the court may require the Administrator to provide the materials and to pay you up to $110 a day until you receive the materials, unless the materials were not sent due to reasons beyond
the control of the Administrator. If you have a claim which is denied or ignored, in whole or in part, you may file suit in a federal court. If it should happen that you are discriminated against for asserting your rights, you may seek assistance
from the U.S. Department of Labor, or you may file suit in a federal court. 
 In any case, the court will decide who will pay court costs
and legal fees. If you are successful, the court may order the person you have sued to pay these costs and fees. If you lose, the court may order you to pay these costs and fees, for example, if it finds that your claim is frivolous. 

If you have any questions regarding the Plan, please contact the Administrator. If you have any questions about this statement or about your
rights under ERISA, you may contact the nearest area office of the Employee Benefits Security Administration (formerly the Pension and Welfare Benefits Administration), U.S. Department of Labor, listed in your telephone directory, or the Division of
Technical Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution Avenue, N.W. Washington, D.C. 20210. You also may obtain certain publications about your rights and responsibilities under
ERISA by calling the publications hotline of the Employee Benefits Security Administration. 
 o 0 o 

  
 - 12 - 

 EXHIBIT A 

  
 - 13 - 

 EXHIBIT B 

SEPARATION AGREEMENT AND RELEASE 

This Separation Agreement and Release (“Agreement”) is made by and between
                    (“Employee”) and Pharmacyclics, Inc. (the “Company”) (collectively referred to as the “Parties” or
individually referred to as a “Party”). 
 Whereas, in connection with Employee’s termination of employment effective as of
            , 201    , Employee is eligible to receive the severance benefits provided in the Pharmacyclics, Inc. Change in Control and Severance Plan effective as of
March 4, 2015 (the “Plan”), subject to the terms and conditions set forth therein including (but not limited to) entering into a release of claims agreement in favor of the Company under Section 5 of the Plan. 

Whereas, in consideration for such severance benefits provided under the Plan pursuant to Section 5 of the Plan, the Parties wish to
resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions, and demands that Employee may have against the Company and any of the Releasees as defined below, including, but not limited to, any and all claims arising
out of or in any way related to Employee’s employment with or separation from the Company. 
 Now, therefore, Employee covenants and
agrees as follows: 
 1. Payment of Salary and Receipt of All Benefits. Employee acknowledges and represents that, other than the
severance benefits set forth in the Plan and Participation Agreement, the Company has paid or provided all salary, wages, bonuses, accrued vacation/paid time off, premiums, leaves, housing allowances, relocation costs, interest, severance,
outplacement costs, fees, reimbursable expenses, commissions, stock, stock options, vesting, and any and all other benefits and compensation due to Employee. 

2. Release of Claims. Employee agrees that the foregoing consideration represents settlement in full of all outstanding obligations
owed to Employee by the Company and its current and former officers, directors, employees, agents, investors, attorneys, shareholders, administrators, affiliates, benefit plans, plan administrators, insurers, trustees, divisions, and subsidiaries,
and predecessor and successor corporations and assigns (collectively, the “Releasees”). Employee, on his/her own behalf and on behalf of his/her respective heirs, family members, executors, agents, and assigns, hereby and forever releases
the Releasees from, and agrees not to sue concerning, or in any manner to institute, prosecute, or pursue, any claim, complaint, charge, duty, obligation, demand, or cause of action relating to any matters of any kind, whether presently known or
unknown, suspected or unsuspected, that Employee may possess against any of the Releasees arising from any omissions, acts, facts, or damages that have occurred up until and including the Effective Date (as defined below) of this Agreement,
including, without limitation: 
 a. any and all claims relating to or arising from Employee’s employment relationship with the Company
and the termination of that relationship; 

  
 - 14 - 

 b. any and all claims relating to, or arising from, Employee’s right to purchase, or actual
purchase of shares of stock of the Company, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty, breach of duty under applicable state corporate law, and securities fraud under any state or federal law;

 c. any and all claims for wrongful discharge of employment; termination in violation of public policy; discrimination; harassment;
retaliation; breach of contract, both express and implied; breach of covenant of good faith and fair dealing, both express and implied; promissory estoppel; negligent or intentional infliction of emotional distress; fraud; negligent or intentional
misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair business practices; defamation; libel; slander; negligence; personal injury; assault; battery; invasion of privacy; false imprisonment;
conversion; and disability benefits; 
 d. any and all claims for violation of any federal, state, or municipal statute, including, but not
limited to, Title VII of the Civil Rights Act of 1964; the Civil Rights Act of 1991; the Rehabilitation Act of 1973; the Americans with Disabilities Act of 1990; the Equal Pay Act; the Fair Labor Standards Act; the Fair Credit Reporting Act;
the Age Discrimination in Employment Act of 1967; the Older Workers Benefit Protection Act; the Employee Retirement Income Security Act of 1974; the Worker Adjustment and Retraining Notification Act; the Family and Medical Leave Act; the
Sarbanes-Oxley Act of 2002; the California Family Rights Act; the California Labor Code; the California Workers’ Compensation Act; and the California Fair Employment and Housing Act; 

e. any and all claims for violation of the federal or any state constitution; 

f. any and all claims arising out of any other laws and regulations relating to employment or employment discrimination; 

g. any claim for any loss, cost, damage, or expense arising out of any dispute over the nonwithholding or other tax treatment of any of the
proceeds received by Employee as a result of this Agreement; and 
 h. any and all claims for attorneys’ fees and costs. 

Employee agrees that the release set forth in this section shall be and remain in effect in all respects as a complete general release as to
the matters released. This release does not extend to any obligations incurred under this Agreement. This release does not release claims that cannot be released as a matter of law, including, but not limited to, Employee’s right to file a
charge with or participate in a charge by the Equal Employment Opportunity Commission, or any other local, state, or federal administrative body or government agency that is authorized to enforce or administer laws related to employment, against the
Company (with the understanding that any such filing or participation does not give Employee the right to recover any monetary damages against the Company; Employee’s release of claims herein bars Employee from recovering such monetary relief
from the Company). Further, to the extent applicable, Employee will not be deemed to have waived his/her right to indemnification in accordance with the Company’s certificate of incorporation and bylaws or any agreement between Employee and the

  
 - 15 - 

 
Company. Employee represents that he/she has made no assignment or transfer of any right, claim, complaint, charge, duty, obligation, demand, cause of action, or other matter waived or released
by this Section. 
 3. Acknowledgment of Waiver of Claims under ADEA. [The following provision to be included if Employee is at least
40 years of age:] Employee acknowledges that he/she is waiving and releasing any rights he/she may have under the Age Discrimination in Employment Act of 1967 (“ADEA”), and that this waiver and release is knowing and voluntary. Employee
agrees that this waiver and release does not apply to any rights or claims that may arise under the ADEA after the Effective Date of this Agreement. Employee acknowledges that the consideration given for this waiver and release is in addition to
anything of value to which Employee was already entitled. Employee further acknowledges that he/she has been advised by this writing that: (a) he/she should consult with an attorney prior to executing this Agreement; (b) he/she has
twenty-one (21) days within which to consider this Agreement; (c) he/she has seven (7) days following his/her execution of this Agreement to revoke this Agreement; (d) this Agreement shall not be effective until after the
revocation period has expired; and (e) nothing in this Agreement prevents or precludes Employee from challenging or seeking a determination in good faith of the validity of this waiver under the ADEA, nor does it impose any condition precedent,
penalties, or costs for doing so, unless specifically authorized by federal law. In the event Employee signs this Agreement and returns it to the Company in less than the 21-day period identified above, Employee hereby acknowledges that he/she has
freely and voluntarily chosen to waive the time period allotted for considering this Agreement. Employee acknowledges and understands that revocation must be accomplished by a written notification to the person executing this Agreement on the
Company’s behalf that is received prior to the Effective Date. 
 4. California Civil Code Section 1542. Employee
acknowledges that he/she has been advised to consult with legal counsel and is familiar with the provisions of California Civil Code Section 1542, a statute that otherwise prohibits the release of unknown claims, which provides as follows: 

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING
THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR. 
 Employee, being aware of
said code section, agrees to expressly waive any rights he/she may have thereunder, as well as under any other statute or common law principles of similar effect. 

5. Trade Secrets and Confidential Information/Company Property. Employee shall continue to maintain the confidentiality of all
confidential and proprietary information of the Company and shall continue to comply with the terms and conditions of any proprietary information (the “Confidentiality Agreement”) between Employee and the Company. Employee agrees that the
above reaffirmation and agreement with the Confidentiality Agreement shall constitute a new and separately enforceable agreement to abide by the terms of the 

  
 - 16 - 

 
Confidentiality Agreement, entered and effective as of the Effective Date. Employee specifically acknowledges and agrees that any violation of the restrictive covenants in the Confidentiality
Agreement shall constitute a material breach of this Agreement. Employee shall return all the Company property and confidential and proprietary information in Employee’s possession to the Company on the Effective Date of this Agreement. 

6. Entire Agreement. This Agreement represents the entire agreement and understanding between the Company and Employee concerning the
subject matter of this Agreement and Employee’s employment with and separation from the Company and the events leading thereto and associated therewith, and supersedes and replaces any and all prior agreements and understandings concerning the
subject matter of this Agreement and Employee’s relationship with the Company, with the exception of the Confidentiality Agreement. 

7. No Oral Modification. This Agreement may only be amended in a writing signed by Employee and the Company’s Chief Executive
Officer. 
 8. Governing Law. This Agreement shall be governed by the laws of the State of California, without regard for
choice-of-law provisions. Employee consents to personal and exclusive jurisdiction and venue in the State of California. 
 9. Effective
Date. [Employee understands that this Agreement shall be null and void if not executed by him/her within twenty one (21) days. Each Party has seven (7) days after that Party signs this Agreement to revoke it. This Agreement will
become effective on the eighth (8th) day after Employee signed this Agreement, so long as it has been signed by the Parties and has not been revoked by either Party before that date (the “Effective Date”).]/OR/[If Employee is under
age 40, the following provision will apply: Employee understands that this Agreement shall be null and void if not executed by him/her within seven (7) days. This Agreement will become effective on the date it has been signed by both
Parties (the “Effective Date”).] 
 10. Voluntary Execution of Agreement. Employee understands and agrees that he/she
executed this Agreement voluntarily, without any duress or undue influence on the part or behalf of the Company or any third party, with the full intent of releasing all of his/her claims against the Company and any of the other Releasees. Employee
acknowledges that: 
  

	 	(a)	he/she has read this Agreement; 

  

	 	(b)	he/she has been represented in the preparation, negotiation, and execution of this Agreement by legal counsel of his/her own choice or has elected not to retain legal counsel; 

 

	 	(c)	he/she understands the terms and consequences of this Agreement and of the releases it contains; and 

  

	 	(d)	he/she is fully aware of the legal and binding effect of this Agreement. 

  
 - 17 - 

 IN WITNESS WHEREOF, the Parties have executed this Agreement on the respective dates set forth
below. 
  

											
									[NAME], an individual
					
	Dated:            , 201    								  

									[Name]
					
									PHARMACYCLICS, INC.
						
	Dated:            , 201    								By		  

											  [Name, Title]

  
 - 18 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]